Nicotine patch and lozenge are effective for women

被引:29
作者
Shiffman, S
Sweeney, CT
Dresler, CM
机构
[1] Pinney Assoc, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Pittsburgh, PA 15260 USA
[3] Pinney Assoc, Bethesda, MD USA
[4] GlaxoSmithKline Consumer Healthcare, Parsippany, NJ USA
关键词
D O I
10.1080/14622200412331328439
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
It has been hypothesized that women may be less likely to obtain therapeutic benefit from nicotine replacement therapy (NRT). The present study tested this hypothesis, using two different types of NRT medications. A secondary analysis of two randomized clinical trials was performed: One compared active 21-mg nicotine patch with placebo among 193 men and 309 women, and the other compared active 2-mg or 4-mg nicotine lozenge with placebo among 788 men and 1,030 women. Using logistic regression analysis of 6-month continuous abstinence and survival analysis, we assessed the efficacy of patch and lozenge among women and tested for a gender x treatment interaction. Active NRT was more effective than placebo among women, for both patch and lozenge. In the lozenge trial, women were less successful than men. The gender x treatment interaction was not significant in either study, whether assessed by logistic regression or survival analysis. In the lozenge trial, gender moderated the effects of smoking rate and dependence (but not treatment) on outcome: These variables affected success rates only among women. Treatment with nicotine patch or lozenge is effective for women, and the analysis did not reveal significant gender differences in efficacy. Gender differences in outcome may be moderated by nicotine dependence.
引用
收藏
页码:119 / 127
页数:9
相关论文
共 32 条
[1]  
[Anonymous], 1991, JAMA, V266, P3133
[2]   Gender differences in the pharmacology of nicotine addiction [J].
Benowitz, NL ;
Hatsukami, D .
ADDICTION BIOLOGY, 1998, 3 (04) :383-404
[3]   Gender differences in quit rates following smoking cessation with combination nicotine therapy: Influence of baseline smoking behavior [J].
Bohadana, A ;
Nilsson, F ;
Rasmussen, T ;
Martinet, Y .
NICOTINE & TOBACCO RESEARCH, 2003, 5 (01) :111-116
[4]   Predicting smoking cessation and major depression in nicotine-dependent smokers [J].
Breslau, N ;
Johnson, EO .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2000, 90 (07) :1122-1127
[5]  
Burton S L, 2000, MMWR Morb Mortal Wkly Rep, V49, P665
[6]   Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling [J].
Collins, BN ;
Wileyto, EP ;
Patterson, F ;
Rukstalis, M ;
Audrain-McGovern, J ;
Kaufmann, V ;
Pinto, A ;
Hawk, L ;
Niaura, R ;
Epstein, LH ;
Lerman, C .
NICOTINE & TOBACCO RESEARCH, 2004, 6 (01) :27-+
[7]   Bupropion for smoking cessation - Predictors of successful outcome [J].
Dale, LC ;
Glover, ED ;
Sahs, DPL ;
Schroeder, DR ;
Offord, KP ;
Croghan, IT ;
Hurt, RD .
CHEST, 2001, 119 (05) :1357-1364
[8]  
DRESLER CM, 2003, EUROPEAN RESP MONOGR, V8, P146
[9]   MEASURING NICOTINE DEPENDENCE - A REVIEW OF THE FAGERSTROM TOLERANCE QUESTIONNAIRE [J].
FAGERSTROM, KO ;
SCHNEIDER, NG .
JOURNAL OF BEHAVIORAL MEDICINE, 1989, 12 (02) :159-182